The Institute for Clinical and Economic Review (ICER) explains that, compared with anti–tumor necrosis factor (anti-TNF) drugs, both guselkumab and risankizumab offered a superior benefit based on currently available data.
The Institute for Clinical and Economic Review (ICER) released a Final Condition Update report and a Report-at-a-Glance on immunomodulators for the treatment of moderate to severe plaque psoriasis.
The updated report incorporates new clinical data and cost information for therapies that have been previously reviewed, as well as analyses of more recently approved medications such as guselkumab (Tremfya), tildrakizumab (Ilumya) and certolizumab pegol (Cimzia). Also included within the report were data on risankizumab, which is currently under review by the FDA.
Click here to read more about IL-23 inhibitors.
At a July 2018 public meeting of the New England Comparative Effectiveness Public Advisory Council, the group voted that, compared with anti—tumor necrosis factor (anti-TNF) drugs, both guselkumab and risankizumab offered a superior benefit based on currently available data.
“Similar to the findings of our 2016 report, we again found that many targeted therapies offer benefit over non-targeted therapies, and we are able to further clarify which agents may be most effective,” said Dan Ollendorf, PhD, ICER’s Chief Scientific Officer in a statement.
In addition to the clinical benefits of these medications, ICER recognized that these therapies appear to reduce complexity of care, reduce burdens on family members and caregivers, and improve patients’ ability to work. The report also noted that these therapies use a novel mechanism of action, which allows for new treatments to be effective for patients for whom previous therapies have failed.
However, ICER noted that the evidence was not adequate to show a net health benefit of tildrakizumab compared with anti-TNF agents, or of the anti-TNF agent certolizumab pegol over other subcutaneously administered TNF inhibitors, such as adalimumab (Humira) and etanercept (Enbrel).
Based on the findings of the report, ICER updated its policy recommendations to say that insurers should consider the limitation or cancellation of step therapy approaches to coverage for these drugs, as patients and clinicians have reiterated that step therapy delays improvements to patients’ quality of life. Manufacturers, it adds, should be transparent in the rationale for any increases in drug prices.
“While many of these therapies currently represent reasonable value, patients continue to face insurance barriers that interfere with their access to these potentially life-changing therapies, and recent price increases for many agents may further limit access,” said Ollendorf.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Switching Patterns Highlight Nocebo Effect in European Patients Using Amgevita
July 23rd 2024About half of the patients in a European study who transitioned from reference adalimumab to a biosimilar version stayed on the biosimilar at the 1-year mark. However, researchers warned about a possible nocebo effect resulting in some patients switching back to the originator.
Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report
May 19th 2024The discussion highlights key emerging trends from the Festival of Biologics conference and the annual Cardinal Health Biosimilars Report, including the importance of sustainability in the health care landscape and the challenges and successes in biosimilar adoption and affordability.
Real-World Study: No Increase in Health Resource Costs After Infliximab Biosimilar Introduction
July 20th 2024Although biosimilars reduce drug purchasing costs for hospitals, it’s unclear whether those savings might be offset by increased health resource utilization following a non-medical switching initiative.